Skip to main content

Year: 2023

Ebix Announces Q3 2023 Results

JOHNS CREEK, Ga., Nov. 14, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial services, travel, healthcare, and e-learning industries today announced the following results for the quarter ended September 30, 2023:Q3 2023 GAAP Revenues of $119.2 million, with 1.1% Year-over-Year decline vs. Q3 2022 Non-GAAP Revenues of $120.5 million (with all revenues normalized on a net basis). On a GAAP basis, Q3 2022 revenues were $257.9 million (with pre-paid card revenues on a gross basis in Q3 2022). Constant currency GAAP Revenues of $121.8 million in Q3 2023 increased 0.8% Year-over-Year as compared to Non-GAAP Revenue of $120.5 million in Q3 2022. The Year-to-date(YTD) Constant currency GAAP Revenue of $379.3 million as of Q3 2023...

Continue reading

Essential Oils Market Size Worth USD 27.13 Billion by 2032 | Emergen Research

Rising demand for essential oils in the aromatherapy industry and increasing need for natural ingredients are key factors driving essential oils market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global essential oils market size was USD 8.80 Billion in 2022 and is expected to register a rapid revenue CAGR of 11.9% during the forecast period. The surge in demand for essential oils is attributed to their widespread adoption in the aromatherapy industry and the increasing preference for natural ingredients. Essential oils, derived from natural plant extracts, are gaining popularity due to their safety and absence of side effects. In contrast to synthetic alternatives, these oils do not impede bodily functions or leave harmful residues. The shift towards natural and organic products, especially among health-conscious...

Continue reading

Global Particle Board Market Size to Reach Value of USD 31.91 Billion by 2032 | Emergen Research

Rising furniture industry demand and increasing prevalence of infrastructural and construction projects across the globe are some of the key factors driving the Particle Board market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global particle board market, valued at USD 22.20 Billion in 2022, is projected to exhibit a steady 3.7% revenue CAGR in the upcoming years. The surge in furniture industry demand, coupled with accessible raw materials and a global uptick in construction projects, primarily fuels this growth. Particle board, a cost-effective and versatile material, plays a pivotal role in furniture manufacturing. Its preference over other wood-based panels stems from being lighter, more manageable, and offering a smooth surface for various finishes, elevating both appearance and durability. The market...

Continue reading

Global Pico Laser Market Size to Reach USD 468.03 Million in 2032 | Emergen Research

Rapid developments in pico laser technologies and Increasing number of aesthetic and cosmetic procedures is a key factor driving Pico Laser market revenue growth. Vancouver, Nov. 14, 2023 (GLOBE NEWSWIRE) — The global pico laser market size was USD Million 225.4 in 2022 and is expected to register a steady revenue CAGR of 7.7% during the forecast period, according to latest analysis by Emergen Research. Rising tattoo removal practices across countries and technological advancements in laser technologies and medical procedures are major factors driving market revenue growth. A Picosecond laser is a cutting-edge technique that can lessen pigmentation caused by inflammation, which generate short pulses of light, typically less than one picosecond. Unique characteristics of this technology has paved way for material processing that...

Continue reading

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive cancer patients; published median overall survival of 7-11 months with FDA approved ICI1 Announced 2-year overall survival rate of 74% in VERSATILE-002 Phase 2 trial of ICI-naïve HPV16-positive recurrent or metastatic head and neck cancer patients; published 2-year overall survival of less than 30% with FDA approved ICI1 Announced interim safety and immune response data for Phase 1/2 clinical trial evaluating docetaxel and PDS01ADC in metastatic prostate cancer patients; PSA decline was seen in all 18 patients and 61% of patients had at least a 60% decrease in PSA levels Company to host conference call and webcast today at 8:00 AM ESTPRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology...

Continue reading

Base Carbon Reports Third-Quarter 2023 Financial Results

TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Base Carbon Inc. (NEO: BCBN) (OTCQX: BCBNF) (“Base Carbon”, or the “Company”) is pleased to announce its third-quarter 2023 consolidated financial results. All financial references are denominated in U.S. dollars, unless otherwise noted. Company Highlights for the Three and Nine Months Ended September 30, 2023:In Q3 2023, the Company executed an agreement with Value Network Ventures Advisory Services Pte Ltd. (“VNV”), through wholly owned subsidiary Base Carbon Capital Partners Corp., to facilitate the development of a nature-based carbon removal project, focused on the reforestation of degraded rural farmlands in the northern Indian state of Uttar Pradesh (the “India ARR Project”). Deployed initial $3.6mm in India ARR Project capital towards the planting of approximately 6.5 million...

Continue reading

Eneti Inc. Announces Financial Results for the Third Quarter of 2023 and Declares a Quarterly Cash Dividend

MONACO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Eneti Inc. (NYSE: NETI) (“Eneti” or the “Company”), today reported its results for the three months ended September 30, 2023. The Company also announced that on November 14, 2023 its board of directors (the “Board of Directors”) declared a quarterly cash dividend of $0.01 per share on the Company’s common shares. Results for the Three and Nine Months Ended September 30, 2023 and 2022For the third quarter of 2023, the Company’s GAAP net income was $18.3 million, or $0.48 per diluted share, including transaction costs of $0.2 million or $0.01 per diluted share, consisting primarily of legal and tax services related to its pending business combination with Cadeler A/S. These transaction costs are recorded in General and Administrative expenses. Total revenues for the third quarter of 2023...

Continue reading

Intermap Announces 46% Increase in Commercial Revenue During the Third Quarter

Driven by subscription-based, as-a-service solutions adopted by major global insurance underwriters Investing in readiness to meet pending foreign government awards DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced third quarter results. For the period ending September 30, 2023, the Company reported revenue of $1.5 million, compared with $1.2 million for the third quarter of 2022 and $1.5 million in the second quarter of 2023. Intermap recognized a 35% increase in subscription-based revenue year-over-year for the third quarter, driven by the expansion of its European insurance segment and growth in insurance software license values. Value-added data increased to $0.4 million...

Continue reading

AppTech Payments Corp. Reports Third Quarter 2023 Results

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce between business-to-business and business-to-consumer, today announced results for its third quarter ended September 30, 2023. The financial statements and 10-Q are available on sec.gov. Third Quarter and Year-to-Date 2023 Financial HighlightsRevenue was approximately $140 thousand for the three months ended September 30, 2023, representing an increase of 22% from the same prior-year quarter. The increase was principally driven by incremental licensing revenue in 2023. Revenue was approximately $363 thousand for the nine months ended September 30, 2023, representing an increase of 6% from the same prior-year period. The increase was principally driven by incremental licensing revenue...

Continue reading

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic company growth strategy to create a cost effective, coordinated, streamlined approach to operations to increase value for patients and shareholders Presented preclinical data for DPI-125 at the Society of Neuroscience Annual Meeting 2023 on November 13, 2023; results supported further development of DPI-125 as a potential treatment of opioid use disorder SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) —  DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products to combat the fentanyl and substance...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.